

[COVER PAGE]

TABLE OF CONTENTS

DRAFT

EXECUTIVE SUMMARY

DRAFT

REPORT OF THE ADVISORY TASK FORCE
ON LOWERING PHARMACEUTICAL PRICES

I. [INTRODUCTION]

II. [OVERVIEW OF TASK FORCE / THE PROBLEM / GENERAL STATISTICS ON DRUG SPENDING AND PRICING INCREASES]

A. Overview and Structure of the Task Force.

B. Understanding and Quantifying the Problem.

C. The Players Involved In the Pricing of Pharmaceuticals.

1. Manufacturers.

2. Drug Distributors/Wholesalers.

3. Pharmacy Benefit Managers (PBMs).

4. Insurers and Managed Care Firms.

5. Physicians.

6. Pharmacists and Pharmacies.

7. Patients.

8. Government.

D. The Current Federal and State Legal Landscape.

1. Selected Federal Laws and Regulations.

2. Selected State Laws and Regulations.

E. Examples of Unconscionable Pharmaceutical Pricing Practices.

1. Case Study #1—[brand name drug]

2. Case Study #2—[generic drug]

3. Case Study #3—[biosimilar drug]

4. Case Study #4—[manufacturer business model]

F. How Unconscionable Drug Prices and Price Increases Harm Minnesotans.

1. Insured Minnesotans.

2. Underinsured Minnesotans.

3. Uninsured Minnesotans.

4. Impact on Native Americans.

III. [SIGNIFICANT CAUSES AND CONTRIBUTORS DRIVING DRUG PRICES HIGHER]

A. [impact of federal patent and intellectual property laws on drug prices]

- B. [antitrust issues impact on drug prices - market concentration / too few manufacturers; price fixing; monopolization; etc.]
 - C. [lack of transparency in how drug prices are determined and its impact on drug prices to consumers]
 - D. [role and influence of PBMs and insurance companies on drug prices]
 - E. [laws prohibiting importation of drugs from other countries]
 - F. [failure of federal and state governments to effectively, or sometimes at all, negotiate rebates and discounts for the drugs they purchase]
 - G. [prescription drug discount coupons and Patient Assistance Programs (PAPs) and their impact on drug prices]
- IV. [PAST AND CURRENT LEGISLATIVE, REGULATORY, AND LAW ENFORCEMENT STRATEGIES TO ADDRESS DRUG PRICES]
- A. Past State and Federal Legislative and Regulatory Strategies to Address High Drug Prices.
 - B. Current State and Federal Legislative and Regulatory Strategies to Address High Drug Prices.
 - C. Current Law Enforcement Strategies to Address High Drug Prices.
- V. [STRATEGIC ANALYSIS AND FEASIBILITY OF POSSIBLE SOLUTIONS]
- VI. [THE TASK FORCE'S RECOMMENDATIONS ON SOLUTIONS TO PRIORITIZE IN ATTEMPTING TO COMBAT SOARING PHARMACEUTICAL DRUG PRICES]

- A. Recommendations for the Minnesota Legislature.**
- B. Recommendations for the United States Congress.**
- C. Recommendations for Regulators of Those Involved in the Pharmaceutical Sales and Distribution Chain.**
- D. Recommendations for Federal and State Law Enforcement Agencies.**
- E. Recommendations for State Agencies that Purchase Pharmaceuticals.**

VII. [CONCLUSION / NEXT STEPS]

DRAFT